No popular authors found.
Ads by Google:


No categories found.

Get's E-Newsletter

Ads by Google:

Follow / Share

Twitter Facebook Google Plus Pinterest RSS Podcast Email  Get Email Alerts

Popular Articles

No popular articles found. Sponsors:

Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, "Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance."

This patent, which expires on May 27, 2029, provides broad coverage for treating celiac disease using orally administered antibodies produced by the Company's proprietary platform technology.  This newly issued patent includes claims covering the composition of matter for Avaxia's AVX-176 antibody, currently in development for celiac disease.

"We are pleased to receive this new patent," stated Barbara Fox, PhD, CEO of Avaxia Biologics.  "This is an important milestone for our company as it is our first issued patent and it validates that the company can obtain composition of matter claims for products derived from our antibody technology platform.  We are actively building a strong IP portfolio with additional patent applications that will cover the broad range of disease applications the company has created with its oral antibody technology."

Dr. Fox added, "This first patent covers AVX-176, an orally administered antibody designed to bind to gluten, the dietary protein that provokes celiac disease in susceptible patients. 
Ads by Google:

We are currently conducting an NIH supported program to advance the development of AVX-176 into pre-clinical models of celiac disease.  Preliminary in vitro data are encouraging and we hope to be able to develop a product in the near future."
About celiac disease: Celiac disease is an inherited, autoimmune disease in which the lining of the small intestine is damaged from eating gluten and other proteins found in wheat, barley, rye, and possibly oats.  Celiac disease is also known as celiac sprue, nontropical sprue, and gluten-sensitive enteropathy.  The disease can develop at any point in life, from infancy to late adulthood.  The symptoms of celiac disease can vary significantly from person to person with the most common being abdominal bloating and pain, chronic diarrhea, vomiting, constipation and weight loss.  There is no medication available to treat the disease.  Patients must follow a lifelong gluten-free diet in an attempt to avoid symptoms.  More than 2 million people in the United States have the disease, or about 1 in 133 people.

About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.

As always, welcomes your comments (see below).

Spread The Word

1 Response:

Patricia Sharp

said this on
21 Jun 2012 6:15:02 AM PDT
I am an unofficially diagnosed celiac, perhaps a non celiac gluten sensitive individual. How would this development help me? When will it be available to the public? Are there any local trials (Oklahoma City)?

Leave a reply:
Your Name *: Email (private) *:

In's Forum Now:

It seems like you really need a concrete or near concrete answer so I would say maybe you ought to get the gene testing. Then you can decide on the gluten challenge. Thanks! I am convinced our dogs are there waiting for us. Meanwhile they are playing, running, laughing, barking & chas...

I can't help thinking that all of this would be so much easier if the doctor I went to 10 years ago would have done testing for celiac, rather than tell me I probably should avoid gluten. He was looking to sell allergy shots and hormone treatment, he had nothing to gain from me being diagnosed ce...

Most (90%-95%) patients with celiac disease have 1 or 2 copies of HLA-DQ2 haplotype (see below), while the remainder have HLA-DQ8 haplotype. Rare exceptions to these associations have been occasionally seen. In 1 study of celiac disease, only 0.7% of patients with celiac disease lacked the HLA al...

This is not quite as cut & dried as it sounds. Although rare, there are diagnosed celiacs who do not have either of those genes. Ravenwoodglass, who posted above, is one of those people. I think she has double DQ9 genes? Am I right Raven? My point is, that getting the gene testing is not an...

Why yes it is! jmg and myself are NCIS, I mean NCGS specialist/experts or is it NCGI people ourselves. posterboy,